MH IV Contrast Conservation Guidance – Click TOC Item to Follow

General – Updated 5.12.22 ................................................................. 1
Pharmacy – Updated 5.12.22 ............................................................... 1
Guidance for Conservation of Iodinated Contrast Agents as it Relates to Acute Stroke –
Updated 5.6.22 ............................................................................... 1
Cardiovascular Service Line – Updated 5.10.22 ................................. 2
Contrast Preservation in the Work-Up of PE – Updated 5.13.22 ................. 3
5.13.22: ......................................................................................... 6
Vascular Surgery Ambulatory Care Guidance for Contrast Conservation – Updated
5.13.22: ......................................................................................... 6
Oncology – Updated 5.10.22 ............................................................... 7
Links to Resources from the ACR Committee on Drugs and Contrast Media: ........ 8
Regional Stakeholders .................................................................. 8

General – Updated 5.12.22

• Reduce IV contrast load on body CTs by 25%
• Reduce IV contrast load on CT angiography (EXCEPT FOR RUN OFFS) by 20%
• All chest cts aside from angiograms/pulmonary arteriograms should generally be Non
  Contrast
  ○ Excluding pediatric
• No IV Contrast for pyelonephritis; use non-contrast or ultrasound
• No IV Contrast for trip and/or fall trauma unless free fluid seen or patient is high risk
  and/or clinically unstable
• Curtail all elective CTs as best as able

Pharmacy – Updated 5.12.22

• Allowing for split dosing of single use product presentations w/in automated contrast
  system as long as done w/in 4 hours and vial is only punctured once.
• Allowing for repackaging of contrast under clean room environment but limiting beyond
  use dating at this time of 8 hours for bulk packaging and 4 hours for single use packaging
  (i.e. seeing this as useful option for pain clinic uses)

Guidance for Conservation of Iodinated Contrast Agents as it Relates to
Acute Stroke – Updated 5.6.22

Recommendations: The following priorities should help structure acute decision making
regarding the use of CT angiography in acute stroke.

Priority 1 Patients: Patients presenting with sudden onset neurological deficits that are
suggestive of a large vessel occlusion with a time last known well of 24 hours require a CTA to
be done emergently.

• Symptoms that localize to the MCA: Contralateral hemiparesis +/- hemianesthesia, eye
deviation away from hemiparesis, aphasia, neglect
• Symptoms that localize to the ACA: Contralateral leg weakness +/- proximal arm weakness
  +/- sensory deficits

Contact Moriah Folsom for updates or corrections. Edited: 5/13/22
- **Symptoms that localize to the posterior circulation**: Sudden onset depressed level of consciousness or coma, quadriplegia or hemiplegia, cranial nerve deficits (diplopia, dysarthria, dysphagia), nystagmus, vertigo, N/V, ataxia (DDx peripheral vertigo), visual field cut.

**Priority 2 patients**: Patients with sudden onset focal neurological deficits that could be due to a large vessel occlusion but lack the features of priority 1 patients should undergo CTA unless there is a critical shortage of contrast.

**Patients who should NOT undergo CTA emergently**: Consider non-urgent MRI/MRA if stroke is considered likely after initial evaluation:

- **Patients with non-disabling symptoms**:
  - Isolated sensory loss or paresthesias, mild dysarthria or isolated facial palsy, mild weakness of a limb that does not impair hand function or gait, mild aphasia that does not impair a patient’s ability to effectively communicate, speech that is slow or stuttering, but otherwise intact (no dysarthria, no aphasia)

- **Patients with non-localizing symptoms**:
  - Non-specific dizziness/lightheadedness, isolated headache that is not a thunderclap headache, confusion/disorientation without any localizing signs, bilateral numbness, isolated dysarthria
  - NOTE: Non-localizing symptoms *could be* due to a stroke, especially if accompanied by other localizing signs/symptoms of stroke, are acute in onset, are in a patient with significant vascular risk factors. A complete neurological examination is required to assess for objective findings of neurological deficits.

- **Patients transferred from outside hospitals** who have had prior CTA that is available in Impax should not have repeat CTAs on arrival to MMC, rather should only have CT perfusion studies.

- **If the initial head CT shows hemorrhage**, a CTA should not automatically follow. Images should be rapidly reviewed by Neurology and Radiology:
  - **Indications for URGENT vascular imaging in the setting of intracranial hemorrhage** AND medical futility is not suspected based on extent of hemorrhage on head CT: Subarachnoid hemorrhage, primary intraventricular hemorrhage, parenchymal hematoma immediately adjacent to large vessels, suspected or known history of infective endocarditis, age ≤50
  - Radiographic abnormalities suspicion for underlying vascular malformation or central venous thrombosis

---

**Cardiovascular Service Line – Updated 5.10.22**

**Conservation**:  
- Avoid opening contrast for routine vascular  
- Cath: Eliminate ventriculograms unless highly indicated (STEMI)  
- EP: Eliminated CT for pulmonary vein anatomy  
- EP: limit contrast for Bi-V and ablation cases

Contact Moriah Folsom for updates or corrections. Edited: 5/13/22
- Dilute contrast

**Active triage**
- Thoracic Aneursym, AAA
- TAVR urgent cases only
  - Diagnostic cath-delay low risk
- Delay CTO cases

**Alternative Modality Use**
- Switch optiray for Conray or CO2 in vascular hybrid
- AAA- use ultrasound
- Thoracic aneurysms-when feasible non-contrast CT for surveillance
- CTA coronary-substitute nuclear cardiac stress or cardiac cath

**Local vs MMC Cath: Triage tool – UNITE**
- GRACE 2 (30 day CV mortality): High Risk ≥145
- Additional clinical risk factors:
  - Hemodynamic instability or cardiogenic shock
  - Recurrent chest pain refractory to Med Rx
  - Recurrent dynamic ST changes particularly with intermittent ST elev
  - Life-threatening arrhythmia or cardiac arrest
  - Mechanical complications of MI
  - Acute CHF
  - High pretest probability of requiring PCI (clinical story, ECG, trop, Previous Dz, recent functional study)

**Contrast Preservation in the Work-Up of PE – Updated 5.13.22**

**Once a patient is deemed low risk for PE (by using clinical gestalt, Well’s criteria, etc)** providers must use PERC criteria to determine the need to order a D-Dimer.

If the patient PERCs positive, then order a D-Dimer and use YEARS criteria to guide further testing. YEARS uses D Dimer cutoffs as opposed to a low, fixed upper limit of normal. (If no YEARS criteria are present, use an upper limit of normal of >/=1000. If any YEARS criteria are present, use >/=500.)

Other mitigation methods could include:
- Use of Ultrasound for DVT to rule in the diagnosis of PE if positive. CTA could then be avoided if the patient is low risk and hemodynamically stable.
- (Use of V/Q in low risk patients with normal CXRs could be considered, however, there is also a shortage of xenon and not all LHS have access to nuclear medicine.)
  - This approach is challenged by limited access to US and V/Q across the system. It would frequently require empiric anticoagulation pending the test.

Note that this approach (the use of empiric anticoagulation and a delayed alternative study) would be best suited for stable, low risk patients. Further, it should be understood that some patients (patients that will need admission regardless of the result) that are empirically anticoagulated and awaiting delayed testing, may need to be admitted with testing pending to avoid ED boarding.


Contact Moriah Folsom for updates or corrections. Edited: 5/13/22
Pulmonary embolism rule-our criteria (PERC)

Used to exclude PE in patients known to have a low pre-test probability (< 15%)

<table>
<thead>
<tr>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≥ 50</td>
</tr>
<tr>
<td>Heart rate ≥ 100</td>
</tr>
<tr>
<td>Oxygen saturations ≤ 94%</td>
</tr>
<tr>
<td>Previous DVT or PE</td>
</tr>
<tr>
<td>Recent surgery or trauma in the past 4 weeks</td>
</tr>
<tr>
<td>Haemoptysis</td>
</tr>
<tr>
<td>Unilateral leg swelling</td>
</tr>
<tr>
<td>Oestrogen use (e.g. HRT, contraceptives)</td>
</tr>
</tbody>
</table>

If all of the above are absent the post-test probability of PE is < 2%

PE continued on next page...
<table>
<thead>
<tr>
<th>No criteria fulfilled</th>
<th>≥ 1 criteria fulfilled</th>
</tr>
</thead>
<tbody>
<tr>
<td>D-dimers &lt;1000 ng/mL</td>
<td>D-dimers &gt;1000 ng/mL</td>
</tr>
<tr>
<td>PE excluded</td>
<td>CTPA</td>
</tr>
<tr>
<td>D-dimers &lt;500 ng/mL</td>
<td>PE excluded</td>
</tr>
<tr>
<td></td>
<td>CTPA</td>
</tr>
</tbody>
</table>

CTPA, Computer tomography pulmonary angiography; DVT, deep vein thrombosis; PE, pulmonary embolism

**OR supply and decision for transition:**
- Currently, we have 110 vials of Omnipaque, which equates to just over two weeks supply.
  - When the Omnipaque runs out, we will convert to Conray 60%.

**Our surgeons are all aware of this and we will:**
- Postpone angiogram procedures for elective conditions (this is quite rare currently anyway)
- Give clear expectations at OR briefing of contrast needs to only open what is likely to be used/needed. Our OR techs and nurses are involved in this.
- Consider CO2 angiography when appropriate for patient condition/anatomy
- We already only use ½ strength for all studies but will use lower concentrations when feasible and with adjuncts (i.e. in insufflator)

Vascular Surgery Ambulatory Care Guidance for Contrast Conservation – Updated 5.13.22:

In order to keep patients on the same surveillance schedule, the following can be done. Please note, this excludes most 1 month follow-up CTAs after repair (those should generally proceed as close to scheduled as possible with contrast as ordered. If questions on those specific test needs, please ask the providers on case by case basis)

For thoracic aneurysm/TEVAR monitoring, we can get non-con CTs just to assess for growth. 1 months scans may be able to be done via NCCT with appropriate modifications in our surveillance protocols otherwise (i.e. down the line get a CTA).

For EVAR surveillance we can continue Duplex as scheduled. If a CTA was ordered in a long term surveillance patient please ask on a case by case basis whether a NCCT can be substituted. 1 months scans may be able to be done via NCCT or duplex with appropriate modifications in our surveillance protocols otherwise (i.e. down the line get a CTA)

For occlusive disease, in lieu of a CTA A/P with runoff we can use arterial duplex more liberally. On case by case basis for suspected aortoiliac disease could elect for diagnostic angiogram. An angiogram compared to CTA uses far less contrast overall and we could supplement with CO2. We may be able to increase SMHC volume to 4 studies per day if they are likely to be diagnostic. This will have to be decided by the providers.

Contact Moriah Folsom for updates or corrections. Edited: 5/13/22
<table>
<thead>
<tr>
<th>Tier Level</th>
<th>Description</th>
<th>Examples</th>
</tr>
</thead>
</table>
| Tier 1     | Evaluation for life-threatening signs/symptoms or for “time critical” emergent diagnoses | • Stroke  
• Trauma  
• R/o pulmonary embolus  
• Acute abdominal pain with peritoneal signs |
| Tier 2     | Acute, higher-risk symptoms or to inform urgent/ acute treatment decisions | • Diagnostic test for cancer signs/symptoms (e.g., unexplained weight loss, hemoptysis, etc.)  
• Initial staging of a cancer diagnosis  
• Evaluation of interim response to cancer treatment *while on active treatment with measurable disease* or when future treatment decisions would be impacted by imaging results  
• Evaluation of palpable mass not appropriate for U/S or MR imaging  
• Acute abdominal pain without peritoneal signs |
| Tier 3     | Imaging related to clinical trials/contract research | • If patient does not meet Tier #1 or #2 above and when imaging “with contrast” is explicitly required by research protocol |
| Tier 4     | Chronic, lower-risk symptoms | • Evaluation of interim response to *adjuvant cancer treatment in patients without measurable disease*  
• Chronic abdominal pain |
| Tier 5     | Chronic disease surveillance/follow-up | • Routine cancer surveillance after conclusion of active treatment (e.g., neck cancer surveillance) |
| Tier 6     | Elective diagnostic or screening tests | • Surgical planning for a non-urgent/non-emergent surgery  
• Non-emergent coronary artery CT with contrast |
Links to Resources from the ACR Committee on Drugs and Contrast Media:

- [Statement and Recommendations](#)
- [ACR Contrast Manual](#)
- **APPENDIX A: Contrast Media Specifications Table**
- [ACR Appropriateness Criteria: Use AC Portal to search for alternative imaging studies for a given indication by clicking on the “Explore by scenario” icon](#)
- [CDC: Protect Patients Against Preventable Harm from Improper Use of Single–Dose/Single–Use Vials](#)
- [ASHP: Considerations for Imaging Contrast Shortage Management and Conservation](#)

### Regional Stakeholders

<table>
<thead>
<tr>
<th>Location</th>
<th>Contacts</th>
</tr>
</thead>
</table>
| Franklin         | Dr. George Hunter
|                  | Radiology Dir: Chris Bailey                                               |
|                  | CMO: Ross Isacke                                                         |
| Maine Medical    | Joel Botler                                                              |
|                  | Sharon Siegel                                                           |
|                  | Jennifer McCarthy                                                       |
| Memorial         | CMO: Matt Dunn                                                           |
|                  | CNO: Kris Dascoulias                                                     |
| Lincoln Health   | DI: Pam Hepburn                                                          |
|                  | Pharmacy: Karen Philbrick                                                |
|                  | ED: Dr Tracy Tippie                                                     |
|                  | Radiologist: Dr Charlie Mullen                                          |
|                  | CMO: Tim Fox                                                            |
| Mid Coast        | DI Director: Alison Lampke                                                |
|                  | Pharmacy: Kevin Dumas                                                    |
|                  | COO: Joe Grant                                                          |
|                  | Radiologist Med Dir: Keith Fleming                                       |
|                  | ED: Ranjiv Advani and AnnMarie Lattanzi                                  |
|                  | CMO: Chris Bowe                                                          |
| Pen Bay/Waldo    | Mark Eggena                                                              |
|                  | Denise Needham                                                           |
|                  | Susan Walker                                                            |
| Southern Maine   | Radiology Admin lead: Cheryl Parker                                      |
|                  | Radiologist: Christina Cinelli                                           |
|                  | ER: Kimberly Perreault                                                   |
|                  | Pharmacy: Jed Lundin                                                     |
|                  | CMO: Mike Albaum                                                         |
| Stephens Memorial| Admin 1: Lissa Merrill                                                   |
|                  | Admin 2: Tim Ingram                                                     |
|                  | Radiologist: Rob Baril                                                  |
|                  | ED: James Gallea                                                        |
|                  | Pharmacy: NA                                                            |
|                  | CMO: Ryan Knapp                                                         |

Contact Moriah Folsom for updates or corrections. Edited: 5/13/22